Extraction form for project: Screening for Glaucoma in Adults - 1 of 2

Design Details

1. Study design

Arms

Arm NameArm Description
A. Selective laser trabeculoplasty (SLT): 1% apraclonidine drop, then 360°
B. Latanoprost (no details given)

Sample Characteristics

1. N
A. Selective laser trabeculoplasty (SLT): 1% apraclonidine drop, then 360°
B. Latanoprost (no details given)
Total
2. Baseline population
A. Selective laser trabeculoplasty (SLT): 1% apraclonidine drop, then 360°
B. Latanoprost (no details given)
Total

Outcomes

TypeDomainSpecific measurement (i.e., tool/definition/specific outcome)PopulationsTimepoints
CategoricalVision disorderMean intraocular pressure (IOP) reduction (SD) at 5 years
  • All Participants
  • end of study

Risk of Bias Assessment

1. Random assignment
2. Allocation concealed
3. Groups similar at baseline
4. Eligibility criteria specified
5. Blinding: outcome assessors or data analysts
6. Intention-to-treat analysis
7. Reporting of attrition, contamination, etc.
8. Differential loss to followup or overall high loss to followup
9. Appropriate analysis including cluster correlation
10. Funding source
11. Randomization adequate?
12. Allocation concealment adequate?
13. Groups similar at baseline?
14. Eligibility criteria specified?
15. Outcome assessors masked?
16. Care provider masked?
17. Patient masked?
18. Attrition and withdrawals reported?
19. Loss to followup differential/ high?
20. People analyzed in the groups in which they were randomized?
21. Quality

Results

Categorical


Vision disorder (Mean intraocular pressure (IOP) reduction (SD) at 5 years)

All Participants
Descriptive StatisticsBetween Arm Comparisons
A. Selective laser trabeculoplasty (SLT): 1% apraclonidine drop, then 360°B. Latanoprost (no details given)
end of study
Standard deviation (SD)
Odds Ratio (OR)
95% CI low (OR)
95% CI high (OR)
p value
Within Arm ComparisonsNet Comparisons
A. Selective laser trabeculoplasty (SLT): 1% apraclonidine drop, then 360°B. Latanoprost (no details given)